Alnylam Pharmaceuticals Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Alnylam Pharmaceuticals Inc inventory turnover ratio, the Alnylam Pharmaceuticals Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 12.28 in the third quarter 2026, a new company high. Average inventory processing period, for the Alnylam Pharmaceuticals Inc in Sep 30 2026 quarter, has decreased to 30 days, compare to 32 days, in the Jun 30 2026 quarter.

Within Healthcare sector 24 other companies have achieved higher inventory turnover ratio. While inventory turnover ranking remained unchanged in the Third Quarter 2026 compared to previous quarter at no. 335.

ALNY Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Alnylam Pharmaceuticals Inc Market Share?

What is Inventory Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Inventory Turnover▼

None ▼

Inventory Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALNY Inventory Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Inventory Growth	40.49 %	35.46 %	28.12 %	5.36 %	-0.79 %
Y / Y Cost of Sales Growth	83.41 %	110 %	195.68 %	160.81 %	140.58 %
Inventory Turnover Ratio (TTM)	12.28	11.45	10.38	9.17	7.04
ALNY's Total Ranking	# 335	# 335	# 468	# 468	#
Average inventory processing period	30	32	35	40	52
Seq. Inventory Growth	9.06 %	15.57 %	1.58 %	9.73 %	5.15 %
Seq. Cost of Sales Growth	21.29 %	43.73 %	-22.49 %	35.74 %	38.87 %

Inventory Turnover Ratio Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 4
Healthcare Sector	# 25
Overall Market	# 335

Inventory Turnover Ratio Statistics
High	Average	Low
12.28	3.19	0.35
(Sep 30 2026)		(Jun 30 2019)

ALNY Company Profile >> Back to ALNY Efficiency Comparisons >> Compare ALNY Inventory Turnover Ratio to its Competitors

Financial Statements
Alnylam Pharmaceuticals Inc 's Inventories	$ 106 Millions	Visit ALNY's Balance sheet
Alnylam Pharmaceuticals Inc 's Cost of Revenues TTM	$ 1,135 Millions	Visit ALNY's Income Statement
What are ALNY's Sales?		Visit ALNY's Sales by Segment

Other Inventory Turnover Ratios
Alnylam Pharmaceuticals Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
ALNY's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for ALNY's Competitors
Inventory Turnover Ratio for ALNY's Suppliers
Inventory Turnover Ratio for ALNY's Customers

You may also want to know
ALNY's Sales Growth Rates	ALNY's Pe Price to earnings ratio	ALNY's Receivables Turnover Ratio	ALNY's Stock Quote
ALNY's Net Income Growth Rates	ALNY's Ps Price to Sales ratio	ALNY's Sales per Employee	ALNY's Asset Turnover Ratio
ALNY's Net Margin	ALNY's Pb Price to Book ratio	ALNY's Financial Strength Ratios	ALNY's Dividend Payout Ratio

Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Inventory Turnover Ratio	Cost of revenues at quarter ending Sep 30 2026	Inventories at quarter ending Sep 30 2026
Teladoc Health Inc	23.99	$ 775.669 Millions	$ 32 Millions
Cryo cell International Inc	16.60	$ 6.680 Millions	$ 0 Millions
Alnylam Pharmaceuticals Inc	12.28	$ 1,135.254 Millions	$ 92 Millions
Vanda Pharmaceuticals Inc	8.70	$ 14.704 Millions	$ 2 Millions
Phathom Pharmaceuticals Inc	7.76	$ 53.106 Millions	$ 7 Millions
Carlisle Companies Incorporated	6.99	$ 3,406.400 Millions	$ 488 Millions
Caredx Inc	6.42	$ 111.106 Millions	$ 17 Millions
Bristol myers Squibb Company	5.65	$ 15,389.000 Millions	$ 2,722 Millions
Avantor Inc	5.48	$ 4,539.200 Millions	$ 828 Millions
Integer Holdings Corporation	4.98	$ 1,376.268 Millions	$ 276 Millions
Ge Healthcare Technologies Inc	4.69	$ 11,372.000 Millions	$ 2,425 Millions
West Pharmaceutical Services Inc	4.69	$ 2,120.200 Millions	$ 452 Millions
Medinotec Inc	4.28	$ 5.143 Millions	$ 1 Millions
3m Company	4.02	$ 15,267.000 Millions	$ 3,801 Millions
Novocure Limited	3.98	$ 166.721 Millions	$ 42 Millions
Incyte Corporation	3.79	$ 439.399 Millions	$ 116 Millions
Baxter International Inc	3.57	$ 8,117.000 Millions	$ 2,277 Millions
Bausch Health Companies Inc	3.54	$ 4,518.000 Millions	$ 1,276 Millions
Exelixis Inc	3.49	$ 93.324 Millions	$ 27 Millions
Mimedx Group Inc	2.98	$ 70.562 Millions	$ 24 Millions
Neogen Corporation	2.89	$ 464.774 Millions	$ 161 Millions
Biomerica Inc	2.65	$ 4.297 Millions	$ 2 Millions
Dexcom Inc	2.65	$ 1,867.500 Millions	$ 705 Millions
Angiodynamics Inc	2.50	$ 142.709 Millions	$ 57 Millions
Pro dex Inc	2.45	$ 53.753 Millions	$ 22 Millions
Beta Bionics Inc	2.31	$ 53.285 Millions	$ 23 Millions
Merit Medical Systems Inc	2.25	$ 817.001 Millions	$ 363 Millions
Johnson and Johnson	2.17	$ 32,222.000 Millions	$ 14,824 Millions

Date modified: 2026-10-30T17:00:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.